Recursion (RXRX) Stock Surges on AI Drug Discovery Hype – What’s Driving the Rally?
Recursion Pharmaceuticals closed at $6.04 on Oct. 24, 2025, after volatile trading and a 44% monthly surge. Q2 revenue rose 33% to $19.2 million, but net loss reached $171.9 million as R&D spending climbed. The company completed a $630 million merger with Exscientia and reported $534 million cash on hand. Key drug candidates advanced in clinical trials, with several late-stage readouts expected by year-end.